Newsroom | Galderma US

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Galderma receives FDA approval for Restylane® Contour for cheek augmentation and correction of midface contour deficiencies

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

Cetaphil® Champions Sun Protection Awareness and Education with Dermatologist-led Digital Campaign

Cetaphil® Launches Innovative Digital Campaign to Connect with Millions of Consumers Experiencing Skin Sensitivity

Differin® Celebrates Fourth Annual Retinoid Education Week by Offering People with Acne the Chance to “Get Clear” Through Large-Scale Product Giveaway

Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation

Galderma Announces Launch of Face for Change Program

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Cetaphil Taps Rachel Brosnahan as Creative Consultant for New “Up Close and Sensitive” Digital Campaign

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

Cetaphil® Unveils Premium Product Line with New HydroSensitiv™ Complex That Delivers 48-Hour Hydration

On International Kissing Day, Galderma Shares First-of-its-Kind Phase IV Kissability Study Results Showing Both Subject and Partner Satisfaction with Restylane® Kysse